Xu-Rong Jiang, PhD MD, is an Associate Director in Analytical Biochemistry at MedImmune, LLC, a biologic subdivision of AstraZeneca. Dr. Jiang had previously been a Principal Scientist in Process & Analytical Sciences at Amgen Inc. where he led a group of scientists to develop, qualify and validate potency assays for clinical and commercial protein products. Dr. Jiang’s particular areas of interest are cell-based assays using genetically engineered cell lines, receptor binding assays, and rapid readout assays. Prior to Amgen, Xu-Rong was a Senior Scientist at Geron Corporation focused on gene therapy and cell therapy, high throughput screening and developing regenerative medicine techniques. Dr. Jiang did post-doctoral work at the University of London and received his Ph.D. from St. Bartholomew’s and Royal London Hospital School of Medicine, University of London. He has published more than 20 journal papers and is an assignee of three U.S. patents.